Dual GALNT3/T6 inhibition is more effective in reducing epithelial ovarian cancer cell proliferation, migration, and invasion, whilst GALNT6 may promote the generation of more aggressive phenotypes via the EGFR pathway 14, 25. The gene discussed is GALNT3; the disease is ovarian carcinoma.